Lung cancer diagnosis support with Infervision

by Alma Medical Imaging

2 years ago
InferRead CT Lung, lung cancer

When diagnosing lung cancer at an early stage, proper lung nodule analysis is essential. Diagnostic tools such as Infervision’s InferRead CT Lung play a key role in this.

Immune checkpoint inhibitor atezolizumab as a potential game-changer in the treatment of early-stage NSCLC

by VHIO

3 years ago
cancer, lung cancer, immunotherapy, tumors

With an estimated 2.2 million new cancer cases and 1.8 million deaths globally, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death in 2020, represent...

IRB Barcelona participates in a study that illuminates origins of lung cancer in never smokers

by IRB Barcelona - Instituto de Investigación Biomédica

3 years ago
genomic analysis, mutations, never smokers, lung cancer

A genomic analysis of lung cancer in people with no history of smoking has found that a majority of these tumors arise from the accumulation of mutations caused by natural processes in the body.

Exercise prevents neuronal damage caused by lung cancer treatment

by Hospital Universitari de Bellvitge

4 years ago
Neuro-Oncology, Neuroscience, Cancer, lung cancer, Exercise

A study of IDIBELL, ICO, and Bellvitge University Hospital shows that exercise not only prevents the loss of neuronal tissue caused by chemotherapy and radiotherapy. Also, patients who follow sports g...

Seeking out predictive biomarkers for a longer-term response to immunotherapy against NSCLC

by VHIO

4 years ago
immune-based, lung cancer, biomarkers

While the rapidly emerging arsenal of immune-based therapies continues to show great promise in more effectively tackling an increasing number of tumor types including melanoma and lung cancer, these ...

ORYZON Reports Results for Quarter Ended September 30, 2020 and Provides Corporate Update

by Oryzon Genomics

4 years ago
Oryzon, reports, epigenetics, oncology, iadademstat, neurological diseases, vafidemstat, Personalized Medicine, AML, lung cancer, Covid-19

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...

ORYZON presents efficacy and safety results of its CLEPSIDRA trial with iadademstat in ED-SCLC patients at ESMO-2020

by Oryzon Genomics

4 years ago
lung cancer, CLEPSIDRA, iadademstat, ESMO, epigenetics, drugs

Lung Cancer: The addition of chemotherapy to EGFR inhibitor therapy improved survival in advanced EGFR-mutant NSCLC in two independent studies, compared with targeted therapy alone

by OncoDNA

5 years ago
EGFR, NSCLC, LUNG CANCER, therapy improved, Gefitinib

The addition of chemotherapy to EGFR inhibitor therapy improved survival in advanced EGFR-mutant NSCLC in two independent studies, compared with targeted therapy alone

LUNG CANCER: Despite early encouraging results, the EGFR inhibitor poziotinib failed to meet its primary endpoint in the phase II ZENITH20 tria

by OncoDNA

5 years ago
LUNG CANCER, EGFR, ZENITH20 tria, ZENITH20 trial’s Cohort 1, lung

Despite early encouraging results, the EGFR inhibitor poziotinib failed to meet its primary endpoint in the phase II ZENITH20 trial. For patients with pre-treated NSCLC with EGFR exon 20 insertion mut...

ORYZON presents positive efficacy results on iadademstat in ED-SCLC patients at ESMO-2019

by Oryzon Genomics

5 years ago
iadademstat, lung cancer, hematology

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, announc...

Pivotal announces participation in two clinical trials with a novel investigational immunotherapy drug to treat melanoma and lung cancer

by Pivotal

6 years ago
Pivotal, clinical trials, drug, melanoma, lung cancer

Pivotal, a specialist CRO, has been awarded two clinical trials for a novel investigational immunotherapy drug and patient enrolment has now started. Pivotal will use its deep knowledge of Oncology...

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting

by AbilityPharma

6 years ago
clinical trial, oncology drugs, endometrial cancer, lung cancer, ABTL0812

AbilityPharma (Ability Pharmaceuticals, SL) a biopharmaceutical company developing oncology drugs, announced today that the company will release the first results of the currently ongoing phase 1/2...